Disease · MONDO_0006134

cervical adenosquamous carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cervical adenosquamous carcinoma. Diseases, record MONDO_0006134. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006134

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cervical adenosquamous carcinoma; Open Targets
Open Targets ID: MONDO_0006134; Open Targets
Other names: adenosquamous carcinoma of cervix, adenosquamous cell carcinoma of cervix, adenosquamous cell carcinoma of cervix uteri, adenosquamous cell carcinoma of the cervix, adenosquamous cell carcinoma of the cervix uteri, adenosquamous cell carcinoma of the uterine cervix, adenosquamous cell carcinoma of uterine cervix, cervical adenosquamous cancer, cervical adenosquamous cell carcinoma, cervix adenosquamous cell carcinoma, cervix uteri adenosquamous cell carcinoma, uterine cervix adenosquamous cell carcinoma; Open Targets
Disease Ontology: DOID:5636; Disease Ontology
NCI Thesaurus: C4519; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SERPLULIMAB	CHEMBL4594550	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 antagonist	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 2	https://conductscience.org/library/genes/2618	Drugs and targets
TYMS	Thymidylate synthase	1	Thymidylate synthase inhibitor	Phase 2	https://conductscience.org/library/genes/7298	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02868892	A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas	Phase 2	6	2018-11-02	Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix	PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT06419673	Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer	Phase 2	240		Cervical Cancer	CARBOPLATIN, CISPLATIN, SERPLULIMAB	Its record names the disease	ClinicalTrials.gov
NCT01097252	Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer	Phase 3	104		Cervical Cancers	CISPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT05234905	H101 Combined With Camrelizumab for Recurrent Cervical Cancer	Phase 2	55		Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab	CAMRELIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
21840137	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006134

GET https://conductscience.org/api/diseases/v1/MONDO_0006134/drugs

API reference For AI assistants